152 related articles for article (PubMed ID: 26902604)
1. L-Canavanine Potentiates Cytotoxicity of Chemotherapeutic Drugs in Human Breast Cancer Cells.
Nurcahyanti AD; Wink M
Anticancer Agents Med Chem; 2017; 17(2):206-211. PubMed ID: 26902604
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic potentiation of vinblastine and paclitaxel by L-canavanine in human cervical cancer and hepatocellular carcinoma cells.
Nurcahyanti AD; Wink M
Phytomedicine; 2015 Dec; 22(14):1232-7. PubMed ID: 26655405
[TBL] [Abstract][Full Text] [Related]
3. L-Canavanine potentiates the cytotoxicity of doxorubicin and cisplatin in arginine deprived human cancer cells.
Nurcahyanti AD; Wink M
PeerJ; 2016; 4():e1542. PubMed ID: 26839743
[TBL] [Abstract][Full Text] [Related]
4. L-Canavanine modulates cellular growth, chemosensitivity and P-glycoprotein substrate accumulation in cultured human tumor cell lines.
Worthen DR; Chien L; Tsuboi CP; Mu XY; Bartik MM; Crooks PA
Cancer Lett; 1998 Oct; 132(1-2):229-39. PubMed ID: 10397478
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
7. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Foroodi F; Duivenvoorden WC; Singh G
Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
[TBL] [Abstract][Full Text] [Related]
8. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines.
Zoli W; Ulivi P; Tesei A; Fabbri F; Rosetti M; Maltoni R; Giunchi DC; Ricotti L; Brigliadori G; Vannini I; Amadori D
Breast Cancer Res; 2005; 7(5):R681-9. PubMed ID: 16168113
[TBL] [Abstract][Full Text] [Related]
9. Enhancing therapeutic efficacy in breast cancer: a study on the combined cytotoxic effects of doxorubicin and MPC-3100.
Gökşen Tosun N
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3249-3259. PubMed ID: 37917369
[TBL] [Abstract][Full Text] [Related]
10. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics.
Chekhun VF; Borikun TV; Lukianova NY
Exp Oncol; 2016 Mar; 38(1):26-30. PubMed ID: 27031715
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with 5-fluorouracil and L-canavanine: in vitro and in vivo studies.
Swaffar DS; Ang CY; Desai PB; Rosenthal GA; Thomas DA; Crooks PA; John WJ
Anticancer Drugs; 1995 Aug; 6(4):586-93. PubMed ID: 7579563
[TBL] [Abstract][Full Text] [Related]
12. Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
Kurebayashi J; Nukatsuka M; Sonoo H; Uchida J; Kiniwa M
Cancer Chemother Pharmacol; 2010 Jan; 65(2):219-25. PubMed ID: 19455332
[TBL] [Abstract][Full Text] [Related]
13. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Han GZ; Liu ZJ; Shimoi K; Zhu BT
Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
[TBL] [Abstract][Full Text] [Related]
14. Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
Chang YW; Singh KP
PLoS One; 2017; 12(3):e0174227. PubMed ID: 28323900
[TBL] [Abstract][Full Text] [Related]
15. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Lopez Lopez R; van Rijswijk RE; Wagstaff J; Pinedo HM; Peters GJ
Eur J Cancer; 1994; 30A(10):1545-9. PubMed ID: 7833116
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms.
Alsherbiny MA; Bhuyan DJ; Low MN; Chang D; Li CG
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576262
[TBL] [Abstract][Full Text] [Related]
17. Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer.
Feng C; Zhang H; Chen J; Wang S; Xin Y; Qu Y; Zhang Q; Ji W; Yamashita F; Rui M; Xu X
Int J Pharm; 2019 Apr; 560():191-204. PubMed ID: 30769131
[TBL] [Abstract][Full Text] [Related]
18. Methylglyoxal at metronomic doses sensitizes breast cancer cells to doxorubicin and cisplatin causing synergistic induction of programmed cell death and inhibition of stemness.
Roy A; Sarker S; Upadhyay P; Pal A; Adhikary A; Jana K; Ray M
Biochem Pharmacol; 2018 Oct; 156():322-339. PubMed ID: 30170097
[TBL] [Abstract][Full Text] [Related]
19. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
Viale M; Pastrone I; Pellecchia C; Vannozzi MO; Cafaggi S; Esposito M
Anticancer Drugs; 1998 Jun; 9(5):457-63. PubMed ID: 9660544
[TBL] [Abstract][Full Text] [Related]
20. New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells.
Duarte D; Vale N
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33271968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
